A Phase 2 interventional study of Placebo (for dupilumab) and Dupilumab in Nasal Polyps, sponsored by Sanofi. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-26.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.
Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 7th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2, and was the 1st registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
University of Virginia · Sites in United States
Ages 18–65
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2013.
This study's enrollment of 60 is close to the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 45 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
13 studies in Nasal Polyps by Sanofi: none open now, 4 under way, 3 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 13 studies in Nasal Polyps by Sanofi, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 2, and was the 1st registered.
Sanofi’s Nasal Polyps studies by the year they started, since 2013.
1 of the studies testing dupilumab in Nasal Polyps that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07268313Rigshospitalet, DenmarkComplete Remission After Treatment With Biologics for Nasal Polyps | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing dupilumab in Nasal Polyps, from their registry updates:
Among Sanofi’s 13 in Nasal Polyps:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.
Secondary Objectives:
To evaluate effect of dupilumab with regards to:
Screening period (4 weeks) + Randomized Treatment Period (16 weeks) + Post-Treatment Period (16 weeks) = 36 weeks.
To ensure at least 28 participants with co-morbid asthma needed for subgroup analysis, recruitment of NP participants without co-morbid asthma would stop when approximately 28 participants without asthma were randomized.
Inclusion criteria: participants with:
Exclusion criteria:
Participants who had taken other drugs or prohibited therapy for this study within 2 months before screening or 5 half-lives, whichever was longer:
Participants with asthma having:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
Drug: Placebo (for dupilumab) · Drug: Mometasone furoate nasal spray
Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
Drug: Dupilumab · Drug: Mometasone furoate nasal spray
Solution for injection; Subcutaneous injection.
Solution for injection; Subcutaneous injection.
Also known as: SAR231893, REGN668
Nasal spray, 2 actuations in each nostril twice daily.
Also known as: NASONEX®
Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16
NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.
Time frame: Baseline, Week 16
Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma
NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.
Time frame: Baseline, Week 16
Change From Baseline in Participant Reported Symptoms Scores of Sinusitis at Week 16
Morning symptoms of sinusitis (nasal congestion/obstruction, anterior rhinorrhea \[runny nose\], posterior rhinorrhea \[post nasal drip\], and loss of sense of smell) were assessed using a 0 (no symptoms) - 3 (severe symptoms) categorical scale where higher score indicated severe symptoms.
Time frame: Baseline, Week 16
Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16
Severity of rhinosinusitis symptoms were assessed on a 0 cm (not troublesome) - 10 cm (worst thinkable troublesome) VAS where higher score indicated worst thinkable troublesome.
Time frame: Baseline, Week 16
Change From Baseline in Nasal Peak Inspiratory Flow (NPIF) at Week 16
NPIF evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration and/or expiration expressed in liter per minute.
Time frame: Baseline, Week 16
Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16
UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia)-40 (normal sense of smell), lower score indicated severe smell loss.
Time frame: Baseline, Week 16
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score
CT scan assessment included Lund-Mackay score and percent of the maxillary sinuses occupied by disease. The Lund-Mackay scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses. The total score ranges from 0 (normal) - 24 (more opacified); higher score indicated worse status.
Time frame: Baseline, Week 16
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease
CT scan assessment included Lund-Mackay score and percentage of the area of maxillary sinuses occupied by disease.
Time frame: Baseline, Week 16
Time to First Response in NPS: Kaplan-Meier Estimate at Week 16
The time-to-first response in NPS: time from the date of randomization to the date of first NPS (defined as \>=1 point reduction from baseline score); for participants without NPS \>=1 point reduction, it was censored at the end of treatment date. The median time to first response was not estimated because the number of responses was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of response at Week 16, are presented as the descriptive measure statistics.
Time frame: Baseline to Week 16
Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16
The SNOT-22 was a validated questionnaire to assess the impact of chronic rhinosinusitis on quality of life. The total score may range from 0 (no problem)-110 (worst quality of life), higher scores represented worst quality of life; minimal clinically important change ≥ 8.90.
Time frame: Baseline, Week 16
The study was conducted at 14 sites in 4 countries. A total of 60 participants were randomized between August 2013 and March 2014.
| Milestone | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Started | 30 | 30 |
| Treated (safety population) | 30 | 30 |
| Completed | 23 | 28 |
| Not completed | 7 | 2 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lack of efficacy | 2 | 0 |
NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.
| score on a scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Baseline | 5.67 ± 0.88 | 5.87 ± 1.01 |
| Week 16 | 5.39 ± 1.47 | 3.97 ± 1.9 |
| Change from baseline at Week 16 | -0.26 ± 1.32 | -1.9 ± 1.76 |
NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.
| score on a scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma | 0.27 ± 0.88 | -2.4 ± 2.03 |
Morning symptoms of sinusitis (nasal congestion/obstruction, anterior rhinorrhea \[runny nose\], posterior rhinorrhea \[post nasal drip\], and loss of sense of smell) were assessed using a 0 (no symptoms) - 3 (severe symptoms) categorical scale where higher score indicated severe symptoms.
| score on a scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Congestion/obstruction | -0.26 ± 0.7 | -0.95 ± 0.86 |
| Runny nose | -0.1 ± 0.58 | -0.62 ± 0.9 |
| Post nasal drip | -0.15 ± 0.59 | -0.49 ± 0.78 |
| Loss of sense of smell | -0.3 ± 0.6 | -1.36 ± 1.08 |
Severity of rhinosinusitis symptoms were assessed on a 0 cm (not troublesome) - 10 cm (worst thinkable troublesome) VAS where higher score indicated worst thinkable troublesome.
| centimetre (cm) | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16 | -1.84 ± 3.6 | -4.32 ± 2.75 |
NPIF evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration and/or expiration expressed in liter per minute.
| liter/minute | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| NPIF-Morning | 28.81 ± 34.26 | 61.91 ± 43.39 |
| NPIF-Evening | 26.65 ± 34.31 | 61.25 ± 45.91 |
UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia)-40 (normal sense of smell), lower score indicated severe smell loss.
| score on scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16 | -0.17 ± 5.1 | 15.36 ± 9.61 |
CT scan assessment included Lund-Mackay score and percent of the maxillary sinuses occupied by disease. The Lund-Mackay scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses. The total score ranges from 0 (normal) - 24 (more opacified); higher score indicated worse status.
| score on scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score | -0.23 ± 3.74 | -9.24 ± 4.58 |
CT scan assessment included Lund-Mackay score and percentage of the area of maxillary sinuses occupied by disease.
| percent area | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease | -3.92 ± 20.54 | -35.66 ± 24.28 |
The time-to-first response in NPS: time from the date of randomization to the date of first NPS (defined as \>=1 point reduction from baseline score); for participants without NPS \>=1 point reduction, it was censored at the end of treatment date. The median time to first response was not estimated because the number of responses was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of response at Week 16, are presented as the descriptive measure statistics.
| Probability of response | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Time to First Response in NPS: Kaplan-Meier Estimate at Week 16 | 0.44 (0.242 to 0.638) | 0.828 (0.69 to 0.965) |
The SNOT-22 was a validated questionnaire to assess the impact of chronic rhinosinusitis on quality of life. The total score may range from 0 (no problem)-110 (worst quality of life), higher scores represented worst quality of life; minimal clinically important change ≥ 8.90.
| score on a scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16 | -8.26 ± 17.63 | -29.1 ± 19.9 |
nTSS was the sum of participant-assessed nasal symptom scores for nasal congestion/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale. Total score ranges from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated severe symptoms.
| score on a scale | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| nTSS - Morning | -0.68 ± 1.44 | -2.87 ± 2.09 |
| nTSS - Evening | -0.77 ± 1.48 | -2.9 ± 2.04 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/30 (0%) | 4/30 (13.3%) | 22/30 (73.3%) |
| Dupilumab 300 mg QW | 0/30 (0%) | 2/30 (6.7%) | 27/30 (90%) |
| Event | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| Herpes zosterInfections and infestations | 0/30 | 1/30 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 | 0/30 |
| HypoaesthesiaNervous system disorders | 0/30 | 1/30 |
| MononeuropathyNervous system disorders | 0/30 | 1/30 |
| Transient ischaemic attackNervous system disorders | 1/30 | 0/30 |
| ArrhythmiaCardiac disorders | 0/30 | 1/30 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/30 | 0/30 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 1/30 | 0/30 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/30 | 1/30 |
| Event | Placebo | Dupilumab 300 mg QW |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/30 | 14/30 |
| Injection site reactionGeneral disorders | 2/30 | 12/30 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/30 | 7/30 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/30 | 7/30 |
| HeadacheNervous system disorders | 5/30 | 6/30 |
| BronchitisInfections and infestations | 4/30 | 1/30 |
| Upper respiratory tract infectionInfections and infestations | 0/30 | 4/30 |
| DizzinessNervous system disorders | 1/30 | 3/30 |
| Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders | 3/30 | 0/30 |
| Back painMusculoskeletal and connective tissue disorders | 0/30 | 3/30 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Placebo | Dupilumab 300 mg QW | Total |
|---|---|---|---|
| Mean | 49.3 ± 9.1 | 47.4 ± 9.8 | 48.4 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab 300 mg QW | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 16 | 18 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dupilumab 300 mg QW | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 30 | 28 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Dupilumab 300 mg QW | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 30 | 29 | 59 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Number of participants with asthma(Participants) | Placebo | Dupilumab 300 mg QW | Total |
|---|---|---|---|
| Yes | 19 | 16 | 35 |
| No | 11 | 14 | 25 |
The record gives a start of Aug 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 2 years 7 months after primary completion. A results delay was requested in Nov 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab